ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / SCYX / insiders
VERU (30) NSRX (26) ATHE (45) GRDX (39) ⌘ Pro Terminal β†’

SCYNEXIS Inc. (SCYX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$3.81 +1.06% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.81

SCYNEXIS Inc. (SCYX) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $37.5M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SCYX Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is SCYX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, SCYNEXIS Inc. (NASDAQ: SCYX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $3.81 (+1.06% 1D, market cap $37.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SCYX ranks #867 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does SCYX compare to VERU and NSRX in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SCYX carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, VERU (Veru Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $37.3M) and NSRX (Nasus Pharma Ltd.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $36.0M). Among the 5-stock peer group, SCYX leads on earnings multiple (N/A) while GRDX leads on capital efficiency (-20.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SCYX?
β–Ό

Per SCYX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001178253), SCYNEXIS Inc. generated $20.6M in revenue (+449.9% YoY), -$8.6M in net income, and -$5.3M in free cash flow against $59.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.81 (+0.00%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (28/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510028
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (8)Whales (3)SEC (11)Macro (3)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.4% Base Target
$10 Bull$3 Base$3 Bear
πŸ“¬ FREE SCYX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for SCYX)Realized 20D OHLCV Swing Band: Β±11.8%
Deterministic 5-Pillar Attribution (28/100 Composite)
πŸ” WHY SCYX SCORES 28/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (39% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 4/9

β–² #2 Bullish Driver: Cash Engine Quality+8/20 pts (29% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
36
Grade E$3.99-4.8% Next Q
Q2 (-2Q)
33
Grade E$3.80+0% Next Q
Q3 (-1Q)
31
Grade E$3.80+0.3% Next Q
Current
28
Grade E$3.81-10% Hist 90D Ξ±
Trajectory: E (36) β†’ E (28)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a SCYX Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While SCYX currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.51) and Max Pain ($4.00) forces dealer call-delta covering toward $9.58.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SCYXβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œSCYX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 28%NO 72%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

SCYX Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SCYX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SCYX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SCYX)

  • βœ“Walkthrough of SCYX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
SCYX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -51.59%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $3.86H $3.86L $3.77C $3.81VOL 117.8K
RES: $5.02SUP: $3.54SMA50: $4.51SMA200: $5.53
$8.57$7.20$5.84$4.47$3.11RES $5.02SUP $3.54$3.812026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SCYX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ SCYX Butterfly Map β†’ + Track SCYX β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +449.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SCYX today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for SCYX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SCYX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SCYX)

Health Care Rank #867 of 1015 βš”οΈ VERU vs SCYX Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (SCYX vs. VERU, NSRX, ATHE, GRDX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, SCYNEXIS Inc. (SCYX) ranks #867 by composite RQD confidence (28/100, grade E) and #774 by equity capitalization ($37.5M). Within this direct 5-issuer industry benchmark cohort, SCYX leads on earnings valuation at N/A trailing P/E, while GRDX leads on capital efficiency and profitability with -20.0% ROIC and -30.0% gross margin. ATHE currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with SCYX at 28/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SCYX ACTIVE
SCYNEXIS Inc.
E 28/100 β€” β€” -35.0% +1.06% $37.5M Benchmark Subject
VERU
Veru Inc.
E 30/100 β€” β€” -35.0% -1.37% $37.3M /veru-vs-scyx β†’
NSRX
Nasus Pharma Ltd.
E 26/100 β€” β€” -35.0% +4.21% $36.0M /nsrx-vs-scyx β†’
ATHE
Alterity Therapeutics Limited
D 45/100 β€” β€” β€” -3.24% $39.3M /athe-vs-scyx β†’
GRDX
GridAI Technologies Corp.
D- 39/100 β€” -30.0% -20.0% -3.43% $35.4M /grdx-vs-scyx β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001178253 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SCYNEXIS Inc. (SCYX) reported GAAP revenue of $20.6M (+449.9% vs. FY2024 revenue of $3.7M , and -85.3% cumulative change since FY2023) , GAAP net income of -$8.6M, operating cash flow of -$5.3M, and free cash flow of -$5.3M (+78.0% YoY). On the balance sheet, SCYX closed FY2025 with $59.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $20.6M -$8.6M -$5.3M -$5.3M $59.0M β€”
FY2024 (FY) 2024-12-31 $3.7M -$21.3M -$24.0M -$24.0M $90.6M β€”
FY2023 (FY) 2023-12-31 $140.1M $67.0M $60.2M $60.2M β€” β€”

3. SCYX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SCYX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, SCYNEXIS Inc. (NASDAQ: SCYX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $3.81 (+1.06% 1D, market cap $37.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SCYX ranks #867 in composite RQD confidence.

How does SCYX compare to VERU and NSRX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SCYX carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, VERU (Veru Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $37.3M) and NSRX (Nasus Pharma Ltd.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $36.0M). Among the 5-stock peer group, SCYX leads on earnings multiple (N/A) while GRDX leads on capital efficiency (-20.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SCYX?

Per SCYX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001178253), SCYNEXIS Inc. generated $20.6M in revenue (+449.9% YoY), -$8.6M in net income, and -$5.3M in free cash flow against $59.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SCYX trading relative to its 50-day, 200-day, and 52-week technical levels?

SCYX last traded at $3.81 (+1.06% on volume of 62,940 shares), positioning the stock -15.52% below its 50-day simple moving average ($4.51) and -31.10% below its 200-day simple moving average ($5.53). Across its 52-week range of $3.53 to $9.12, SCYX sits at the 5.0% percentile with a 14-day RSI of 38.9 (NEUTRAL RANGE) and an implied next-earnings move of Β±11.8% ($3.36 to $4.26).

Direct Sub-Reports: SCYX RQD Cockpit SCYX 12M Forecast SCYX Earnings & Move SCYX Dividends & DRIP SCYX Insiders & 13F SCYX Whale Options SCYX Profit Sankey SCYX News & Why
ROARABLE RATING BRIEF β€’ RQD 28/100 (E) βœ“ SEC XBRL & RQD VERIFIED

SCYX β€” SCYNEXIS Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

SCYNEXIS Inc. (SCYX) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.81 (+1.06% 1D, market capitalization $37.5M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of -60.0%, and free cash flow yield of -13.76%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (3/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

SCYNEXIS Inc. (SCYX) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry..0B on a rounded basis. Revenue was reported at $20.6M for FY 2025.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), SCYNEXIS Inc. (SCYX) reported $20.6M in annual revenue (up from $3.7M in FY2024, +449.9% YoY) and -$8.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($140.1M revenue, $67.0M net income) through FY2025, SCYX scaled operating cash flow to -$5.3M and free cash flow to -$5.3M, backed by $59.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -13.76% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.53 – $9.12 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore does not establish upstream suppliers, downstream customers, or sector co-movement partners. Investors should watch for second-order effects tied to the Phase 1 SCY-247 program, including any follow-on trial announcements, partnering or licensing activity, and changes in the company's cash runway given its FY 2025 cash balance of $21.3M against negative free cash flow. Because the Beta is listed at 1.

  • Key Question #1: Can SCYX sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $20.6M and free cash flow of -$5.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SCYX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SCYX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for SCYNEXIS Inc. (SCYX) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to SCYX Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SCYX Bull vs. Bear Conversation Board β€” What's Your Call at $3.81?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SCYX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SCYX:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER β€’ Fundamental Long-Only πŸ‚ BULLISH 🎯 Target: $4.64 (+23.1%)
πŸ“Œ Pinned Debate

SCYX (E β€’ RQD 28/100) operating leverage in Biotechnology: Pharmaceutical Preparations is mispriced at $3.77

The street is overcomplicating SCYNEXIS Inc. (SCYX). SCYX (E β€’ RQD 28/100) operating leverage in Biotechnology: Pharmaceutical Preparations is mispriced at $3.77. With an RQD score of 28/100 (E) and Forensic Balance Sheet at 11/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $4.07.

CapAlloc_Nerd πŸ‚ BULL

@MidwestValue Agree on the RQD 28/100 quality, though with 1.0 beta I'm scaling in with half-size at $3.77 and keeping dry powder in case we test $3.51.

BE BearTrap_Alert RQD DEBATE OPENER β€’ Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $2.87 (-23.9%)
Spot @ $3.77

Negative free cash flow of -$5.3M and an operating margin of -60% against $21.3M in cash leave little margin for error.

Sitting on the sidelines or leaning short SCYX above $3.77. Negative free cash flow of -$5.3M and an operating margin of -60% against $21.3M in cash leave little margin for error.. Until Fundamental Cash Engine (8/20) and FCF yield (-13.76%) inflect higher, upside is capped near $9.12.

LIVE TAPE